Paper - WANFANG MED ONLINE

You Position: Home > Paper

Advances in understanding the role of leptin, adiponectin and resistin in liver fibrogenesis

( views:320, downloads:618 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 2

DOI:: 10.3969/j.issn.1009-3079.2010.02.008

Key Word:: 瘦素;脂联素;抵抗素;肝纤维化;肝星状细胞

Abstract：肝纤维化是肝脏对各种慢性损伤的一种反应,以肝脏细胞外基质异常过度沉积为特征.脂肪细胞因子主要指由脂肪组织分泌的一类多肽分子,其在慢性肝病如非酒精性脂肪性肝病的发病过程中具有重要作用.本文就瘦素、脂联素和抵抗素在肝纤维化中的作用作一综述.

Reference

[1]林家煜,施亚雄,许曼音.脂联素抵抗研究进展[J].2009,(3).
[2]沈红,郑培永,季光,等.脂肪细胞因子在非酒精性脂肪性肝病中的作用[J].2009,(12).
[3]Bahr MJ,Ockenga J,Boker KH,etc.Elevated resistin levels in cirrhosis are associated with the proinflammatory state and altered hepatic glucose metabolism but not with insulin resistance.[J].2006,291(2).
[4]Mak KM,Ren C,Cao Q,etc.Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependant MAPK pathways.[J].2004,279(6).
[5]Tacke F,Luedde T,Trautwein C,etc.High adiponectin in chronic liver disease and cholestasis suggests biliary route of adiponectin excretion in vivo.[J].2005,42(5).
[6]Y, Zhang,R, Proenca,M, Maffei,etc.Positional cloning of the mouse obese gene and its human homologue.[J].1994,372(6505).
[7]Chisholm DJ,Hui J,London R,etc.Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.[J].2008,48(2).
[8]Marra F,Bertolani C.Adipokines in liver diseases.[J].2009,50(3).
[9]Oike Y,Teratani T,Hibi T,etc.Hepatic AdipoR2 signaling plays a protective role against progression of nonalcoholic steatohepatitis in mice.[J].2008,48(2).
[10]Sahai A,Malladi P,Pan X,etc.Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin.[J].2004,287(5).
[11]Gee LL,Wachtel MS,Wozniak SE.Adipose tissue: the new endocrine organ? A review article.[J].2009,54(9).
[12]Kanda D,Kakizaki S,Sohara N,etc.Elevated plasma resistin concentrations in patients with liver cirrhosis.[J].2008,23(1).
[13]C M, Steppan,S T, Bailey,S, Bhat,etc.The hormone resistin links obesity to diabetes.[J].2001,409(6818).
[14]Sancho-Bru P,Mazzinghi B,Romagnani P,etc.Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells.[J].2006,169(6).
[15]Gomez V,Ma H,Lu L,etc.Expression of adiponectin and its receptors in livers of morbidly obese patients with non-alcoholic fatty liver disease.[J].2009,24(2).
[16]Yamauchi T,Kubota N,Hara K,etc.Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome.[J].2006,116(7).
[17]Elferink MG,Szalowska E,Hoek A.Resistin is more abundant in liver than adipose tissue and is not up-regulated by lipopolysaccharide.[J].2009,94(8).
[18]Lieber CS,Cao Q,Mak KM.Leptin enhances alpha1(I) collagen gene expression in LX-2 human hepatic stellate cells through JAK-mediated H2O2-dependent MAPK pathways.[J].2006,97(1).
[19]Mak KM,Cao Q,Lieber CS.Leptin represses matrix metalloproteinase-1 gene expression in LX2 human hepatic stellate cells.[J].2007,46(1).
[20]Atug O,Ozdogan O,Yapali S,etc.Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis.[J].2009,40(4).
[21]Negro F,Dufour JF,Hora C,etc.Connective tissue growth factor, steatosis and fibrosis in patients with chronic hepatitis C.[J].2008,28(3).
[22]Malaguarnera M,Di Rosa M,Nicoletti F.Molecular mechanisms involved in NAFLD progression.[J].2009,87(7).
[23]Lazar MA,Steppan CM.The current biology of resistin.[J].2004,255(4).
[24]Schriemer R,Leclercq IA,Farrell GC,etc.Leptin is essential for the hepatic fibrogenic response to chronic liver injury.[J].2002,37(2).
[25]Torres N,Vazquez-Vela ME,Tovar AR.White adipose tissue as endocrine organ and its role in obesity.[J].2008,39(8).
[26]Trappoliere M,Gelmini S,Guerra CT,etc.Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells[J].2008,47(2).
[27]Horsmans Y,Leclercq IA,Lanthier N.The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis.[J].2009,12(4).
[28]J H, Henriksen,J J, Holst,S, M?ller,etc.Increased circulating leptin in alcoholic cirrhosis: relation to release and disposal.[J].1999,29(6).
[29]Myers MG,Cowley MA,Munzberg H.Mechanisms of leptin action and leptin resistance.[J].2008,70.
[30]Deepa, Uchil,D, Pipalia,M, Chawla,etc.Non-alcoholic fatty liver disease (NAFLD)--the hepatic component of metabolic syndrome.[J].2009,57.
[31]Tsao TS,Ahmad NS,Bogan JS,etc.T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin.[J].2004,101(28).
[32]Rabe K,Lehrke M,Parhofer KG,etc.Adipokines and insulin resistance.[J].2008,14(11/12).
[33]Wang J,Leclercq I,Brymora JM,etc.Kupffer cells mediate leptin-induced liver fibrosis.[J].2009,137(2).
[34]Aygun C,Canturk Z,Konduk T,etc.Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease.[J].2006,18(2).
[35]Brazowski E,Halpern Z,Gertler A,etc.Competitive inhibition of leptin signaling results in amelioration of liver fibrosis through modulation of stellate cell function.[J].2009,49(1).